| Code | CSB-RA890757MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MT-3534, targeting peptidylarginine deiminase 4 (PADI4), a calcium-dependent enzyme that catalyzes the post-translational modification of arginine residues to citrulline in target proteins. PADI4 is predominantly expressed in granulocytes and plays a critical role in chromatin remodeling and gene regulation through histone citrullination. This enzyme has significant implications in autoimmune diseases, particularly rheumatoid arthritis, where aberrant PADI4 activity contributes to the production of anti-citrullinated protein antibodies (ACPAs) and disease pathogenesis. Additionally, PADI4 is implicated in neutrophil extracellular trap (NET) formation, cancer progression, and inflammatory responses.
As a biosimilar to the reference antibody MT-3534, this antibody provides researchers with a reliable tool for investigating PADI4 expression, localization, and function in various cellular contexts. It supports studies examining the role of protein citrullination in immune dysregulation, epigenetic modifications, and disease mechanisms, facilitating advances in understanding PADI4-related pathological processes and potential therapeutic interventions.
There are currently no reviews for this product.